Opendata, web and dolomites

IMMUNISA SIGNED

A Next Generation Immunotherapy for Human Papilloma Virus induced Cervical Cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IMMUNISA project word cloud

Explore the words cloud of the IMMUNISA project. It provides you a very rough idea of what is the project "IMMUNISA" about.

immunisa    prolonged    sites    274    formulated    edge    directed    push    immunotherapy    multidisciplinary    members    extremely    randomised    curative    overlapping    sme    caused    deaths    isa101    proposes    therapy    care    infected    global    works    vaccine    500    radio    chemotherapy    hpv    vaccines    tumour    cervical    translation    prevent    approved    optimal    hpv16    centre    isa101b    pivotal    progression    cancer    incidence    cutting    service    shown    clinical    detected    induce    synergistically    immune    strategy    data    cxca    efficacy    proprietary    standard    treatment    epitopes    countries    regulatory    previously    papillomavirus    free    biotech    combination    vaccination    solid    efficient    surgery    catapult    prophylactic    premalignant    recurrent    patients    underdeveloped    synthetic    therapeutic    once    too    longer    sufficiently    careful    consisting    commercial    trial    framework    lesions    peptides    survival    measured    proteins    cervisa    types    strategic    specialised    risk    fast    human    oncogenic   

Project "IMMUNISA" data sheet

The following table provides information about the project.

Coordinator
KATHOLIEKE UNIVERSITEIT LEUVEN 

Organization address
address: OUDE MARKT 13
city: LEUVEN
postcode: 3000
website: www.kuleuven.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Project website https://www.isa-pharma.com/isa101-hpv16/
 Total cost 5˙999˙999 €
 EC max contribution 5˙999˙999 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2016-RTD
 Funding Scheme RIA
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2022-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) coordinator 496˙875.00
2    INC RESEARCH UK LTD UK (CAMBERLEY) participant 3˙368˙802.00
3    ISA THERAPEUTICS BV NL (LEIDEN) participant 1˙653˙009.00
4    GRANZER HEINZ ULRICH DE (MUNCHEN) participant 267˙187.00
5    TTOPSTART BV NL (UTRECHT) participant 183˙875.00
6    EUROPEAN CANCER PATIENT COALITION BE (BRUXELLES) participant 30˙250.00

Map

 Project objective

Cervical cancer (CxCa) is caused by high risk types of the human papillomavirus (a.o. HPV16). Prophylactic HPV vaccination is not the standard of care in all European countries, and where approved it is not sufficiently adopted. Once infected, these vaccines no longer prevent premalignant lesions and CxCa, which can only be treated with surgery or radio-chemotherapy. However, this is not effective in recurrent/advanced CxCa. In underdeveloped countries, CxCa is often detected when it is too late for curative treatment. With an estimated global incidence of 500.000 new cases of CxCa and 274.000 deaths per year, the need for an effective therapy is extremely high. Targeted immunotherapy is an effective approach to induce a tumour-directed immune response. Previously, members of the IMMUNISA consortium have formulated ISA101, a cancer vaccine consisting of overlapping synthetic long peptides covering all epitopes of the HPV16 oncogenic proteins. ISA101 has shown promising Phase 1 clinical trial results in patients with advanced CxCa where it works synergistically with chemotherapy. IMMUNISA now proposes the multi-centre randomised Phase 2 CervISA-2 trial; a careful assessment of the efficacy of the proprietary ISA101b therapeutic vaccine in combination with chemotherapy for the treatment of CxCa, measured by a prolonged progression free survival. A multidisciplinary collaboration between leading clinical EU sites specialised in CxCa, a partner providing strategic and operational regulatory service and a cutting-edge biotech SME will enable the optimal implementation of the CervISA-2 trial, exploitation activities and overall project dissemination. This is pivotal to catapult further development of ISA101b as a commercial vaccine and push it towards clinical implementation as fast as possible. For ISA101b, IMMUNISA will provide, 1) clinical data on the efficacy, 2) a solid exploitation strategy and 3) the regulatory framework for efficient translation to clinical use.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNISA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNISA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More